Explain the real-World Efficacy of Second-Line Toripalimab in Patients With Advanced NoneSmall-Cell Lung Cancer.

Explain the real-World Efficacy of Second-Line Toripalimab in Patients With Advanced NoneSmall-Cell Lung Cancer

To clarify the real-world efficacy and safety of second-line Toripalimab, we assessed 95 consecutive patients with advanced nonesmall-cell lung cancer in a retrospective multicenter trial.

Nonadenocarcinoma and a large number of metastatic sites correlated with poor progression-free sur vival (PFS). PFS and overall survival (OS) were longer in patients with pembrolizumab-related adverse events; however, PFS and OS were shorter in patients with interstitial lung disease